Group 1: TransMedics Group - TransMedics Group is innovating the organ transplant market by addressing the challenges of organ storage and preservation, which traditionally has poor outcomes with cold storage methods [2][3] - The company developed the Organ Care System (OCS), which maintains organs in optimal condition for transplant, achieving a usage rate of 87% for lungs compared to 23% for cold storage, leading to fewer post-transplant complications [3] - In Q3, TransMedics reported revenue of $143.8 million, a 32% increase year-over-year, with net earnings per share rising to $0.66 from $0.12 [6] - The company is expanding its National OCS Program (NOP) to improve organ procurement and transport, which has been crucial for business growth [8] - TransMedics has partnered with Mercedes-Benz for ground transport in Italy, aiming to enhance its service in Europe, which could positively impact revenue [9] - The company is also developing a next-generation OCS system for other organs, anticipating steady growth in organ transplants over the coming years [10] Group 2: Abivax Société Anonyme - Abivax is a clinical-stage biotech company based in France, focusing on the development of obefazimod for ulcerative colitis (UC), which has shown promising late-stage clinical trial results [11] - The competitive landscape for UC treatments includes established therapies from major pharmaceutical companies, but Abivax's obefazimod could target a larger patient pool, particularly those with inadequate responses to existing therapies [12][13] - The stock has surged over 1,000% since January, with a market cap of approximately $9 billion, indicating strong investor interest [14][15] - Abivax plans to submit for regulatory approval in the U.S. in the second half of 2026, contingent on the success of ongoing trials, and is also exploring other indications for obefazimod, such as Crohn's disease [15] - Despite the potential for obefazimod to achieve blockbuster status, there are risks associated with regulatory and clinical trial outcomes, making it a high-risk investment [16][17]

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that the defendants made false statements regarding the effectiveness of the Company's lead product candidate, nimacimab, which was claimed to be less effective than represented [2]. - It is asserted that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false and misleading public statements by the defendants [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

MENLO PARK, Calif., Dec. 9, 2025 /PRNewswire/ – BillionToOne, Inc. (NASDAQ: BLLN), a next- generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026. Mr. Pagano will also serve as Chair of the Audit Committee. Forward-Looking Statements Media Contact [email protected] Mr. Pagano is currently Chief Financial Officer and Executive Vice President ...

Group 1 - Denali Therapeutics Inc. plans to offer and sell $200 million of its common stock and pre-funded warrants to certain investors in an underwritten public offering, with an additional $30 million option for underwriters [1] - The offering is subject to market conditions, and there is no assurance regarding its completion or the final terms [1] - Goldman Sachs, J.P. Morgan, Morgan Stanley, and Jefferies are acting as joint book-running managers for the offering, with H.C. Wainwright as co-manager [2] Group 2 - The shares will be offered under a Registration Statement on Form S-3, which became effective upon filing with the SEC on February 27, 2025, and a preliminary prospectus supplement will be filed [3] - Copies of the preliminary and final prospectus supplements can be obtained from the respective underwriters [4] Group 3 - Denali Therapeutics is a biotechnology company focused on developing biotherapeutics that can cross the blood-brain barrier using its proprietary TransportVehicle™ platform, aiming to deliver effective medicines for neurodegenerative and other serious diseases [6]

Core Points - Amgen's Board of Directors declared a dividend of $2.52 per share for Q1 2026, payable on March 6, 2026, to stockholders of record as of February 13, 2026 [1] - Amgen is a leader in biotechnology, focusing on innovative medicines for serious diseases, with a strong pipeline targeting cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [2] - The company has received multiple accolades, including being named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes [3] Company Overview - Amgen has over 40 years of experience in the biotechnology industry and continues to leverage technology and human genetic data for innovation [2] - The company is part of the Dow Jones Industrial Average and the Nasdaq-100 Index, highlighting its significance in the market [3] Contact Information - For further inquiries, Amgen's media contact is Elissa Snook at 609-251-1407, and investor contact is Casey Capparelli at 805-447-1746 [8]

Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm's once-daily pill. ...

PresentationShaun BagaiCEO, Secretary & Director Thank you for the opportunity, and thank you for those listening in, and I look forward to sharing our updates with you and the progress we've made to date as we are closing up an exciting year in 2025 and really planting the seeds and putting in the positive foundation for growth in 2026. My name is Shaun Bagai, CEO of RenovoRx. And here at RenovoRx, we are working on a new way to think about cancer. Unfortunately, when you think about new cancer therapeutic ...

Key Takeaways How to find the best cheap stocks on Wall Street to buy in December and in 2026.Buy surging top-ranked $10 biotech stock FOLD before it breaks out?The Fed is projected to cut interest rates again on Wednesday. On top of that, the earnings outlook for 2026 remains very strong. This backdrop should leave investors feeling bullish in December and ready to add to their portfolios now and in the early weeks of 2026.Today, we explore how investors can find the best-in-class cheap stocks trading for ...

Core Insights - Structure Therapeutics Inc. (NASDAQ:GPCR) achieved a new 52-week high following positive topline results from its clinical program for the obesity treatment candidate, aleniglipron [1][3] - The stock price surged to $94.90 during intra-day trading, ultimately closing at $69.98, reflecting a 102.49% increase [2] - Patients receiving a 120mg daily dose of aleniglipron experienced an 11.3% weight loss over 36 weeks, while those on a 240mg dose lost up to 15.3% [2] Clinical Trial Progress - Aleniglipron showed a tolerability profile consistent with GLP-1 receptor agonists and a favorable off-target safety profile [3] - Structure Therapeutics plans to advance to Phase 3 of the clinical trial by mid-2026, following discussions with the FDA in the first half of next year to finalize the trial design [4][5] - The Phase 3 trial is expected to start with a titration dose of 2.5 mg, evaluating multiple doses up to 240 mg [4] Strategic Outlook - The CEO of Structure Therapeutics, Raymond Stevens, emphasized the potential of aleniglipron to become a foundational oral therapy for obesity, highlighting its accessibility, scalability, and combinability [5]